FOR IMMEDIATE RELEASE

Annette Fribourg
Vice President
Correlogic Systems, Inc.
Tel. 301-795-1707
afribourg@correlogic.com

U.S. Patent and Trade Office Grants Two Additional Patents to Correlogic

Quality Assurance Patents Cover Biological Assays, Biochips, and Mass Spectrometry

Rockville, MD – February 19, 2008 -- Correlogic Systems, Inc. today announces that the U.S. Patent and Trademark Office has awarded the company two new patents on February 19, 2008, relating to quality assurance methods for analysis of blood samples in diagnostic assays. U.S. Patent No. 7,333,895 covers various methods to assure that the results of a biological assay are reliable. U.S. Patent No. 7,333,896 covers other quality control methods including a determination as to whether blood serum samples have been handled in a manner acceptable for analysis by mass spectrometry; this patent also covers methods to certify that biochips used for analytical purposes meet appropriate quality control standards. A third QA/QC patent has been allowed by the PTO and is expected to issue this spring.

"These patents and the processes they protect have far-reaching implications for Correlogic's business development as well as the burgeoning field of blood-based diagnostic assays," said Peter Levine, President and CEO, Correlogic Systems, Inc. "The patents underscore our continuing leadership in developing cutting-edge, but practical technologies that address unmet market needs. For our shareholders, these patents are a valuable addition to our growing IP portfolio."

About Correlogic Systems, Inc. Correlogic Systems, Inc. has developed patented technology and processes with a wide variety of applications for biomarker discovery, disease detection, and new drug discovery. The technology's first application has been in the field of proteomics – the study of human proteins. OvaCheck®, a blood test for the early detection of ovarian cancer, is Correlogic's first diagnostic test using its patented "Hidden Patterns" approach. The test is undergoing the final stages of its extensive validation process. Correlogic has entered into marketing agreements with Quest Diagnostics, Inc., and Laboratory Corporation of America for North America. Mitsui & Co., Ltd. and Quest Diagnostics are equity investors in Correlogic. Visit Correlogic at www.correlogic.com.

Cautionary Statement: Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results could differ materially due to, among other things, operational and other difficulties associated with integrating acquired business, general business conditions, competition among managed care companies, rising health costs, trends in medical loss ratios, health care reform, delay in receipt of regulatory and other approvals for pending transactions and other regulatory issues.